Could CureVac Be a Millionaire-Maker Stock?
Since the beginning of the year, shares of German biotech CureVac (NASDAQ: CVAC) are up 43%. That is far better than the industry benchmark's gain of just 1%, as measured by the iShares NASDAQ Biotechnology ETF (NASDAQ: IBB).
Vaccine drugmaker stocks have done really well when they successfully attain regulatory clearance for their candidates. Can investors get rich just off a small bet on CureVac's potential to do that?
Image source: Getty Images.
Source Fool.com
